DVA · Healthcare

DAVITA INC.

Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: what to focus on this earnings window

News · 2026-08-05

• Guidance / OutlookImportance 48 · Surprise 24
  DaVita reaffirmed its full-year 2026 adjusted EPS guidance of $14.10 to $15.20 rather than raising the outlook after its second-quarter report. The company also maintained adjusted operating income guidance of $2.15…
• Products and TechnologyImportance 31 · Surprise 42
  DaVita is expanding access to Expanded Hemodialysis and continuing hemodiafiltration pilots to improve removal of middle molecules and support more personalized kidney care. The rollout follows FDA approval of Nipro’s…
• Market Demand TrendsImportance 20 · Surprise 24
  DaVita reported accelerating U.S. dialysis treatment-volume growth in the second quarter, supported by improved patient mortality and better phosphate-level management. The company’s patient-volume performance was…

10-Q · 2026-08-04

• Share Repurchase ActivityImportance 89 · Surprise 82
  DaVita repurchased 5.243 million shares for $751.3 million during the first six months of 2026, including $382.8 million of Berkshire repurchases and $368.5 million of open-market repurchases. Total repurchases…
• Operating Cash Flow TrendsImportance 69 · Surprise 64
  Six-month operating cash flow increased 60.8% to $810.9 million from $504.2 million in the prior-year period. The improvement included a $264.3 million reduction in accounts-receivable cash use, with accounts…
• Net Income and EPS PerformanceImportance 69 · Surprise 64
  Net income attributable to DaVita increased 27.8% year over year to $462.9 million for the first six months of 2026 from $362.3 million. Second-quarter attributable net income increased 33.1% to $265.4 million from…
• Acquisitions and DivestituresImportance 65 · Surprise 82
  Cash paid for acquisitions increased to $38.5 million in the first six months of 2026 from $10.6 million in the comparable 2025 period, a 263.7% year-over-year increase. Goodwill additions from acquisitions totaled…
• Elara Caring Minority AcquisitionImportance 65 · Surprise 60
  DaVita closed its acquisition of a noncontrolling minority interest in Elara Caring on July 20, 2026 after signing the definitive agreement on February 2, 2026. The company paid $200 million in cash at closing, subject…
• Debt Financing and RepaymentsImportance 64 · Surprise 42
  During the six months ended June 30, 2026, DaVita incurred a $500 million incremental Term Loan B-2 tranche and drew $65 million on its revolving credit facility, while making approximately $36 million of scheduled…
• Reimbursement and Payer MixImportance 64 · Surprise 56
  Medicare and Medicare Advantage generated $3.42 billion of six-month dialysis patient service revenue, up from $3.27 billion, while Medicaid and Managed Medicaid increased to $439.8 million from $424.2 million.…
• Interest Rate EnvironmentImportance 64 · Surprise 42
  DaVita entered into a June 8, 2026 Ninth Amendment that added $500 million to Term Loan B-2, using proceeds to repay part of its revolving-line balance; the transaction generated $2.035 million of debt extinguishment…
• Integrated Kidney Care GrowthImportance 60 · Surprise 40
  As of June 30, 2026, DaVita IKC provided integrated care and disease-management services to approximately 64,900 patients in risk-based integrated care arrangements and another 5,700 patients in other integrated care…
• Revenue Performance and MixImportance 59 · Surprise 48
  Six-month consolidated revenue increased to $6.97 billion from $6.60 billion, with U.S. dialysis revenue rising to $5.92 billion from $5.71 billion and Other—Ancillary services revenue increasing to $1.05 billion from…
• Geographic Market CommentaryImportance 59 · Surprise 48
  DaVita’s international dialysis business operated 595 outpatient dialysis centers across 14 countries outside the United States as of June 30, 2026. International revenue increased 20.9% year over year during the first…
• Interest Rate and Refinancing ExposureImportance 52 · Surprise 42
  On July 7, 2026, DaVita entered into forward interest rate cap agreements with an aggregate notional amount of $750 million. The agreements cap exposure to SOFR variable-rate changes on specified portions of the…
• Regulatory Approval MilestonesImportance 51 · Surprise 50
  In June 2026, the Centers for Medicare & Medicaid Services issued a proposed rule addressing the Medicare End Stage Renal Disease Prospective Payment System for calendar year 2027. CMS estimates that the proposal would…
• Operating Income and MarginsImportance 49 · Surprise 32
  Consolidated operating income increased 8.6% year over year to $1.061 billion for the six months ended June 30, 2026, while total segment operating margin increased 5.2% to $1.107 billion. U.S. dialysis operating…
• Operating Expense TrendsImportance 49 · Surprise 32
  U.S. dialysis patient-care costs increased 3.4% year over year to $3.974 billion for the first six months of 2026, and patient-care cost per treatment increased 3.2% to $278.74. The increase was primarily caused by…
• Revenue Recognition and Contract AssetsImportance 46 · Surprise 56
  DaVita recognized $98.5 million of integrated kidney care revenue for performance obligations satisfied in previous years during the six months ended June 30, 2026, up from $95.9 million in the prior-year period.…
• Regulatory RiskImportance 44 · Surprise 60
  DaVita continues to face government investigations in the United States involving physician joint ventures, medical-director agreements, insurance communications, American Kidney Fund donations, and physician…
• Value-Based Care ContractsImportance 43 · Surprise 32
  DaVita’s integrated kidney care (IKC) risk-based arrangements require estimates of member alignment, third-party medical claims expense, quality outcomes, and risk-adjustment scores. Measurement limitations delayed…
• Treatment Volume TrendsImportance 43 · Surprise 32
  DaVita’s U.S. dialysis treatment volume increased in the second quarter of 2026, with 7.23 million treatments versus 7.03 million in the first quarter and average treatments per day rising 1.1% to 92,649.…
• Liquidity and Cash PositionImportance 43 · Surprise 6
  DaVita had $1.435 billion of available capacity and $65 million drawn under its $1.5 billion revolving credit facility as of June 30, 2026. No letters of credit were outstanding under the revolving facility, while…
• Macroeconomic Factors ImpactImportance 38 · Surprise 42
  The expiration of enhanced Affordable Care Act premium tax credits at the end of 2025 adversely affected Affordable Care Act exchange enrollment and DaVita’s commercial payor mix, reducing revenue per treatment.…
• Capital ExpendituresImportance 36 · Surprise 14
  DaVita invested $271.8 million in property and equipment during the first six months of 2026, up 2.8% from $264.3 million in the prior-year period. U.S. dialysis capital expenditures were $229.5 million, compared with…
• Litigation and Legal RiskImportance 31 · Surprise 42
  A putative class action in the U.S. District Court for the Northern District of Illinois alleges that DaVita and its former chief executive officer violated Section 1 of the Sherman Act through agreements not to…
• Expanded Dialysis Therapy RolloutImportance 31 · Surprise 42
  DaVita identified expanded hemodialysis (expanded HD) and hemodiafiltration (HDF) as treatment pathways that provide middle molecule clearance. The company plans to expand patient access to these therapies when…
• Income Tax Rate ChangesImportance 20 · Surprise 40
  The consolidated effective income tax rate declined to 20.4% for the first six months of 2026 from 22.6% in the prior-year period. The effective tax rate attributable to DaVita Inc. declined to 25.4% from 28.9%, a 3.5…
• Dialysis Center FootprintImportance 18 · Surprise 14
  DaVita’s dialysis-center footprint increased to 2,671 centers operated at June 30, 2026, compared with 2,662 centers at the comparable prior-year period. The footprint includes company-owned or operated outpatient…

8-K · 2026-08-04

• Debt and Liquidity PositionImportance 69 · Surprise 50
  DaVita incurred a $500 million Term Loan B-2 tranche in June 2026 under the Ninth Amendment to its senior secured credit agreement. A portion of the proceeds repaid revolving-credit borrowings, accrued interest and…
• Outstanding IndebtednessImportance 69 · Surprise 50
  In June 2026, DaVita amended its senior secured credit agreement to add a $500 million Term Loan B-2 tranche. A portion of the proceeds repaid borrowings, accrued interest, and fees on the revolving credit line, while…
• Guidance / OutlookImportance 66 · Surprise 24
  DaVita maintained its 2026 adjusted operating income guidance at $2.150 billion to $2.250 billion. Adjusted diluted net income per share guidance remains $14.10 to $15.20, while free cash flow guidance is $1.000…
• Operating Cash Flow TrendsImportance 62 · Surprise 46
  Second-quarter operating cash flow was $490 million, up from $324 million in the second quarter of 2025 and $321 million in the first quarter of 2026. Six-month operating cash flow reached $811 million, compared with…
• Capital Return ProgramImportance 52 · Surprise 42
  DaVita repurchased 2.2 million common shares for $348 million during the second quarter of 2026 at an average price of $154.95 per share. Six-month repurchases totaled 5.243 million shares and $751 million. From July 1…
• Revenue Performance and MixImportance 42 · Surprise 14
  Second-quarter 2026 consolidated revenue was $3.554 billion, up from $3.380 billion in the second quarter of 2025 and $3.416 billion in the first quarter of 2026. U.S. dialysis services and other revenue was $3.012…
• Operating Margin DriversImportance 42 · Surprise 14
  Second-quarter operating income increased to $579 million from $538 million in the second quarter of 2025 and $482 million in the first quarter of 2026. Operating margin was 16.3%, compared with 14.1% sequentially and…
• Operating Expense TrendsImportance 42 · Surprise 14
  Patient-care costs rose to $2.392 billion in the second quarter of 2026 from $2.262 billion in the second quarter of 2025, an increase of $130 million. Six-month patient-care costs were $4.734 billion, up $233 million…
• Integrated Kidney Care ExpansionImportance 39 · Surprise 50
  DaVita reported approximately 64,900 patients in risk-based integrated care arrangements as of June 30, 2026, up from 62,600 at March 31, 2026. These arrangements represented approximately $5.8 billion in annualized…
• Integrated Kidney Care GrowthImportance 31 · Surprise 32
  DaVita had approximately 64,900 patients in risk-based integrated care arrangements as of June 30, 2026, representing approximately $5.8 billion in annualized medical spend. The company also had 5,700 patients in other…
• Capital Expenditure ProgramImportance 25 · Surprise 6
  DaVita spent $175 million on maintenance and development capital expenditures during the second quarter of 2026. Second-quarter maintenance capital expenditures were $123 million for productive-capacity investments,…
• Market Demand TrendsImportance 25 · Surprise 32
  U.S. dialysis treatments totaled 7,226,600 in the second quarter of 2026, averaging 92,649 treatments per day. Average daily treatments increased 1.09% sequentially from the first quarter, while normalized non-acquired…

News · 2026-08-04

• Operating Income and MarginsImportance 52 · Surprise 56
  Second-quarter 2026 operating income reached $579 million, supported by higher dialysis treatment volumes and improved patient outcomes. Net income attributable to DaVita increased to $265 million from $199 million in…
• Free Cash Flow and GuidanceImportance 48 · Surprise 24
  DaVita generated $256 million of free cash flow and $490 million of operating cash flow in the second quarter of 2026. The company reaffirmed 2026 adjusted diluted EPS guidance of $14.10 to $15.20 and adjusted…
• Guidance / OutlookImportance 48 · Surprise 24
  DaVita reaffirmed its full-year 2026 adjusted EPS guidance of $14.10 to $15.20 rather than raising the outlook after its second-quarter report. The company also maintained adjusted operating income guidance of $2.15…
• Reimbursement and Payer MixImportance 46 · Surprise 42
  Revenue per dialysis treatment declined in the second quarter as patients dropped out of Obamacare plans after pandemic-era subsidies ended. The resulting enrollment and commercial-mix shift pressured treatment…
• Capital Return ProgramImportance 34 · Surprise 42
  DaVita repurchased 2.2 million shares during the second quarter of 2026. The company generated $490 million of operating cash flow and $256 million of free cash flow during the quarter. Continued repurchases are…
• Acquisition / Partnership / DivestitureImportance 34 · Surprise 42
  DaVita continued its strategic expansion into value-based and integrated kidney care through its Integrated Kidney Care platform. The company also made an investment in Elara Caring by acquiring a minority interest,…
• Revenue Performance and MixImportance 22 · Surprise 32
  Second-quarter 2026 consolidated revenue increased 5.2% year over year to $3.554 billion, exceeding the $3.50 billion FactSet estimate. U.S. dialysis treatment volume increased, but revenue per treatment declined…
• Market Demand TrendsImportance 20 · Surprise 24
  DaVita reported accelerating U.S. dialysis treatment-volume growth in the second quarter, supported by improved patient mortality and better phosphate-level management. The company’s patient-volume performance was…